Paliperidone Palmitate
Brand names: Invega Hafyera, Invega Sustenna, Invega Trinza
At a glance
- Medicare prescriptions, 2024
- 574,809
- Medicare drug cost
- $1.93B
- Average cost per prescription
- $3,354
- Clinicians who prescribed it
- 13,961
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia in adults. Schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants.
From the FDA-approved prescribing information (label dated February 2025). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA SUSTENNA is not approved for use in patients with dementia-related psychosis..
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatry 41.5%
- Psychiatric Nurse Practitioners 37.6%
- Nurse Practitioners 8.6%
- Physician Assistants 4.2%
- Family Medicine 2.6%
- Internal Medicine 2.3%
- Child & Adolescent Psychiatry 1.4%
- Geriatric Medicine 0.5%
- Neurology 0.4%
- Addiction Medicine 0.2%
- General Practice 0.2%
- Pharmacists 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 15% from 2019 to 2024.
Biggest change by state since 2019
- Maryland +38%
- Iowa +38%
- Minnesota +36%
- New York +30%
- Mississippi +28%
- Alabama (smallest change) +2%
- Louisiana (smallest change) +2%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $4.3M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Janssen Pharmaceuticals, Inc $3.9M
- Luye Pharma (USA) LTD. $300,711
- Janssen Scientific Affairs, LLC $84,528
- Janssen Biotech, Inc. $1,819
- Johnson & Johnson Health Care Systems Inc. $909
- Abiomed $181
- Actelion Pharmaceuticals US, Inc. $77
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.